Tremelimumab
Tremelimumab (Imjudo, AstraZeneca AB) has 2 EU-approved indications in 2 tumour types.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Non-small cell lung cancer1 | |||
No sensitising EGFR mutations or ALK positive mutations | + durvalumab and platinum-based chemotherapy | 1L metastatic | None |
| Hepatocellular carcinoma1 | |||
None | + durvalumab | 1L advanced | None |
Full text of section 4.1 (therapeutic indications)
IMJUDO in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Label history
8 changes to the Imjudo label since 2023, 1 of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes